Brief: Bioxcel Therapeutics Enters Into Asset Sale Agreement With Teva Pharmaceuticals
BRIEF-Bioxcel Therapeutics Enters Into Asset Sale Agreement With Teva Pharmaceuticals Aug 28 (Reuters) - BioXcel Therapeutics Inc BTAI.O:
BIOXCEL THERAPEUTICS ENTERS INTO ASSET SALE AGREEMENT WITH TEVA PHARMACEUTICALS
BIOXCEL THERAPEUTICS - TEVA TO SERVE AS STALKING HORSE BIDDER IN 363 AUCTION PROCESS
BIOXCEL THERAPEUTICS - IGALMI REMAINS COMMERCIALLY AVAILABLE; SUPPLY TO CONTINUE DURING SALE PROCESS
BIOXCEL THERAPEUTICS - SECURES $19 MILLION IN DIP FINANCING FROM EXISTING SECURED LENDERS
BIOXCEL THERAPEUTICS - COMMENCES VOLUNTARY CHAPTER 11 PROCEEDINGS IN U.S. BANKRUPTCY COURT
BIOXCEL THERAPEUTICS - SECURES COMMITMENT FOR DEBTOR-IN-POSSESSION FINANCING
BIOXCEL THERAPEUTICS - ASSET SALE INCLUDES IGALMI AND PENDING SNDA FOR BXCL501 FOR AT-HOME USE
Source text: ID:nGNX1pT326
Further company coverage: BTAI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioXcel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna
Brief: Bioxcel Therapeutics Enters Into Asset Sale Agreement With Teva Pharmaceuticals
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna, Ulta Beauty